VistaGen Therapeutics
VTGN
25 hedge funds and large institutions have $1.33M invested in VistaGen Therapeutics in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
29% more capital invested
Capital invested by funds: $1.02M → $1.33M (+$301K)
14% more funds holding
Funds holding: 22 → 25 (+3)
0.01% more ownership
Funds ownership: 0.15% → 0.16% (+0.01%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$33.3K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$24.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22.3K |
| 4 |
SCM
Sitrin Capital Management
Century City,
California
|
+$20.2K |
| 5 |
RC
RBF Capital
San Francisco,
California
|
+$11.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$19K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9K |
| 3 |
BlackRock
New York
|
-$698 |
| 4 |
GI
Gradient Investments
Arden Hills,
Minnesota
|
-$27 |
VTGN Hedge Fund Activity: Q2 2020 in Review
25 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2020, worth a combined $1.33M — up 29% from $1.02M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VTGN positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $33.3K. The largest seller was Vanguard Group, cutting an estimated $19K.
- 25 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2020, up from 22 in Q1 2020.
- Funds reported $1.33M of VistaGen Therapeutics stock for Q2 2020, up 29% quarter-over-quarter.
- 5 funds opened new VistaGen Therapeutics positions in Q2 2020 and 2 closed out, a net change of +3 holders.
- The largest VistaGen Therapeutics buyer in Q2 2020 was Jane Street, an estimated $33.3K added.
- The largest VistaGen Therapeutics seller in Q2 2020 was Vanguard Group, an estimated $19K sold.
Based on aggregated 13F filings for Q2 2020.